Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment

BACKGROUND: Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Casadei-Gardini, Andrea, Nobili, Stefania, Mini, Enrico, Fancelli, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321521/
https://www.ncbi.nlm.nih.gov/pubmed/32655640
http://dx.doi.org/10.1155/2020/8024124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321521/
https://www.ncbi.nlm.nih.gov/pubmed/32655640
http://dx.doi.org/10.1155/2020/8024124

Ejemplares similares